Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Abbott Labs (ABT) PT Raised to $145 at Jefferies
October 21, 2021 7:56 AM EDTJefferies analyst Raj Denhoy raised the price target on Abbott Labs (NYSE: ABT) to $145.00 (from $135.00) while maintaining a Buy rating following earnings.
The analyst commented, "Key post call datapoints: 1) COVID testing still elevated with $1-$1.4bn baked into 4Q guide, 2) screening versus symptomatic testing... More
Abbott (ABT) Tops Q3 EPS by 47c, Sales Beat
October 20, 2021 7:32 AM EDTAbbott (NYSE: ABT) reported Q3 EPS of $1.40, $0.47 better than the analyst estimate of $0.93. Revenue for the quarter came in at $10.9 billion versus the consensus estimate of $9.44 billion.
GUIDANCE:
Abbott sees FY2021 EPS of $5.00-$5.10, versus the consensus of $4.45.
For earnings history and earnings-related data on Abbott (ABT) click here.
... More